Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 14.74% is 108% above its 5-year average of -191.61%, near the high end of its 5-year range (-6247.08%–71.36%).
107.86% above its 12-month average of -187.45%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2026 (2026-06-30): -218.05%.
EBITDA MARGIN
14.74%
EBITDA MARGIN AVG TTM
-187.45%
EBITDA MARGIN AVG 3Y
-1211.54%
EBITDA MARGIN AVG 5Y
-191.61%
EBITDA MARGIN AVG 10Y
-151.72%
EBITDA MARGIN AVG 15Y
-4343.30%
EBITDA MARGIN AVG 20Y
-4057.86%
CURRENT VS TTM AVG
+107.86%
CURRENT VS 3Y AVG
+101.22%
CURRENT VS 5Y AVG
+107.69%
CURRENT VS 10Y AVG
+109.72%
CURRENT VS 15Y AVG
+100.34%
CURRENT VS 20Y AVG
+100.36%
Arrowhead Pharmaceuticals, Inc.
Market Cap
$8.64B
EBITDA Margin
14.74%
TTM Avg
-187.45%
3Y Avg
-1211.54%
5Y Avg
-191.61%
Market Cap
$8.61B
EBITDA Margin
-870.12%
TTM Avg
-705.14%
3Y Avg
-488.60%
5Y Avg
-370.00%
Market Cap
$8.88B
EBITDA Margin
-340.97%
TTM Avg
-141.29%
3Y Avg
-228.68%
5Y Avg
-264.44%
Market Cap
$8.41B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
Market Cap
$8.95B
EBITDA Margin
-25.09%
TTM Avg
-47.89%
3Y Avg
-132.36%
5Y Avg
-132.36%
Market Cap
$8.95B
EBITDA Margin
13.28%
TTM Avg
13.13%
3Y Avg
16.37%
5Y Avg
17.13%
Market Cap
$9.22B
EBITDA Margin
13.28%
TTM Avg
13.13%
3Y Avg
16.37%
5Y Avg
17.13%
Market Cap
$7.95B
EBITDA Margin
20.05%
TTM Avg
16.44%
3Y Avg
-1944.65%
5Y Avg
-32112.59%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. (ARWR) | $8.64B | 14.74% | -187.45% | -1211.54% | -191.61% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.61B | -870.12% | -705.14% | -488.60% | -370.00% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.88B | -340.97% | -141.29% | -228.68% | -264.44% |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | -3.14% | -1.08% | -5.02% | -19.32% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.95B | -25.09% | -47.89% | -132.36% | -132.36% |
| Bruker Corporation (BRKRP)vs › | $8.95B | 13.28% | 13.13% | 16.37% | 17.13% |
| Bruker Corporation (BRKR)vs › | $9.22B | 13.28% | 13.13% | 16.37% | 17.13% |
| TG Therapeutics, Inc. (TGTX)vs › | $7.95B | 20.05% | 16.44% | -1944.65% | -32112.59% |
| Insulet Corp. (PODD)vs › | $9.30B | 21.67% | 20.24% | 16.36% | 15.66% |
| Vaxcyte, Inc. (PCVX)vs › | $9.54B | N/A | N/A | N/A | N/A |
Gross Margin
100.0%
EBITDA Margin
14.7%
Operating Margin
11.9%
Net Margin
-47.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -218.05% |
| 2026-03-31 | -182.94% |
| 2025-12-31 | 17.88% |
| 2025-09-30 | 19.69% |
| 2025-06-30 | -573.80% |
| 2025-03-31 | 71.36% |
| 2024-12-31 | -6247.08% |
| 2023-12-31 | -3725.20% |
| 2023-09-30 | -649.01% |
| 2023-06-30 | -628.29% |
| 2023-03-31 | 34.75% |
| 2022-12-31 | -63.07% |
| 2022-09-30 | -257.07% |
| 2022-06-30 | -216.94% |
| 2022-03-31 | 29.08% |
| 2021-12-31 | -221.39% |
| 2021-09-30 | -162.94% |
| 2021-06-30 | -65.09% |
| 2021-03-31 | -80.20% |
| 2020-12-31 | -104.24% |
| 2020-09-30 | -633.38% |
| 2020-06-30 | -52.64% |
| 2020-03-31 | -88.69% |
| 2019-12-31 | -12.20% |
| 2019-09-30 | 24.76% |
| 2019-06-30 | 45.90% |
| 2019-03-31 | 48.16% |
| 2018-12-31 | 34.98% |
| 2018-09-30 | -88.32% |
| 2018-06-30 | -2026.94% |
| 2018-03-31 | -2135.07% |
| 2017-12-31 | -361.05% |
| 2017-09-30 | -104.38% |
| 2017-06-30 | -48.72% |
| 2017-03-31 | -55.00% |
| 2016-12-31 | -314.20% |
| 2016-09-30 | -67044.90% |
| 2016-06-30 | -46796.07% |
| 2016-03-31 | -46767.87% |
| 2015-12-31 | -42392.96% |
| 2015-09-30 | -55712.64% |
| 2015-06-30 | -12325.37% |
| 2015-03-31 | -66704.42% |
| 2014-12-31 | -14538.94% |
| 2014-09-30 | -50477.47% |
| 2014-06-30 | -28397.82% |
| 2014-03-31 | -24723.93% |
| 2013-12-31 | -15099.38% |
| 2013-09-30 | -17371.75% |
| 2013-06-30 | -13567.49% |
| 2013-03-31 | -11294.91% |
| 2012-12-31 | -2742.13% |
| 2012-09-30 | -11271.56% |
| 2012-06-30 | -13313.69% |
| 2012-03-31 | -14223.39% |
| 2011-12-31 | -14962.00% |
| 2010-12-31 | -1103.20% |
| 2010-09-30 | -1218.28% |
| 2009-12-31 | -1341.22% |
| 2009-09-30 | -1634.78% |
| 2009-06-30 | -77.44% |
| 2009-03-31 | -2102.61% |
| 2008-12-31 | -1181.22% |
| 2008-09-30 | 18855.72% |
| 2008-06-30 | -4091.20% |
| 2008-03-31 | -928.40% |
| 2007-12-31 | -1638.27% |
| 2007-09-30 | -1964.53% |
| 2007-06-30 | -2111.26% |
| 2006-12-31 | -38253.35% |
| 2006-09-30 | -21687.16% |
| 2006-06-30 | -1743.71% |
| 2006-03-31 | -10011.59% |
| 2005-12-31 | -1538.49% |
| 2005-09-30 | -866.92% |
| 2005-06-30 | -1531.41% |
| 2005-03-31 | -1958.38% |
| 2004-12-31 | -1212.68% |
| 2004-09-30 | -896.01% |
| 2004-06-30 | -1597.57% |
| 2003-06-30 | -6472.46% |
| 2003-03-31 | -3173.37% |
| 2002-12-31 | -1947.80% |
| 2002-09-30 | -1477758.43% |
